640,000 Shares in Silence Therapeutics plc (NASDAQ:SLN) Bought by Eventide Asset Management LLC

Eventide Asset Management LLC bought a new position in Silence Therapeutics plc (NASDAQ:SLN) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 640,000 shares of the company’s stock, valued at approximately $11,635,000. Eventide Asset Management LLC owned approximately 2.14% of Silence Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Values First Advisors Inc. bought a new position in shares of Silence Therapeutics during the third quarter valued at about $56,000. Quarry LP bought a new position in Silence Therapeutics in the second quarter worth about $114,000. Marshall Wace LLP raised its stake in Silence Therapeutics by 7.3% in the second quarter. Marshall Wace LLP now owns 149,397 shares of the company’s stock worth $2,839,000 after buying an additional 10,206 shares in the last quarter. Verition Fund Management LLC bought a new position in Silence Therapeutics in the third quarter worth about $207,000. Finally, Custom Index Systems LLC bought a new position in Silence Therapeutics in the second quarter worth about $282,000. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Trading Up 2.8 %

NASDAQ:SLN opened at $7.67 on Friday. The company’s 50 day moving average price is $16.25 and its 200-day moving average price is $18.34. Silence Therapeutics plc has a 52 week low of $5.81 and a 52 week high of $27.72.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SLN shares. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Jefferies Financial Group began coverage on shares of Silence Therapeutics in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target for the company. Morgan Stanley restated an “overweight” rating and issued a $49.00 price objective on shares of Silence Therapeutics in a report on Tuesday, October 8th. Chardan Capital restated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.